250 related articles for article (PubMed ID: 792355)
41. Assessment of in vitro antifungal efficacy and in vivo toxicity of Amphotericin B-loaded PLGA and PLGA-PEG blend nanoparticles.
Moraes Moreira Carraro TC; Altmeyer C; Maissar Khalil N; Mara Mainardes R
J Mycol Med; 2017 Dec; 27(4):519-529. PubMed ID: 28797532
[TBL] [Abstract][Full Text] [Related]
42. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
Saint-Julien L; Joly V; Seman M; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Dec; 36(12):2722-8. PubMed ID: 1482139
[TBL] [Abstract][Full Text] [Related]
43. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
44. Amphotericin B.
Abadi J
Pediatr Rev; 1995 Oct; 16(10):363-4. PubMed ID: 7479429
[No Abstract] [Full Text] [Related]
45. In vitro antifungal activity of clotrimazole (Bay b 5097).
Shadomy S
Infect Immun; 1971 Aug; 4(2):143-8. PubMed ID: 4949484
[TBL] [Abstract][Full Text] [Related]
46. Effect of amphotericin B on capsule and cell size in Cryptococcus neoformans during murine infection.
Zaragoza O; Mihu C; Casadevall A; Nosanchuk JD
Antimicrob Agents Chemother; 2005 Oct; 49(10):4358-61. PubMed ID: 16189121
[TBL] [Abstract][Full Text] [Related]
47. Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.
Sneller MR; Hariri A; Sorenson WG; Larsh HW
Antimicrob Agents Chemother; 1977 Sep; 12(3):390-4. PubMed ID: 334065
[TBL] [Abstract][Full Text] [Related]
48. Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with Cryptococcal neoformans.
Chintalacharuvu KR; Matolek ZA; Pacheco B; Carriera EM; Beenhouwer DO
Med Mycol; 2021 Nov; 59(11):1085-1091. PubMed ID: 34332505
[TBL] [Abstract][Full Text] [Related]
49. Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.
Ellis NS; Bartlett MS; Smith JW
Am J Clin Pathol; 1979 Aug; 72(2):194-8. PubMed ID: 382827
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion.
Souza LC; Campa A
J Antimicrob Chemother; 1999 Jul; 44(1):77-84. PubMed ID: 10459813
[TBL] [Abstract][Full Text] [Related]
51. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
Ralph ED; Khazindar AM; Barber KR; Grant CW
Antimicrob Agents Chemother; 1991 Jan; 35(1):188-91. PubMed ID: 2014976
[TBL] [Abstract][Full Text] [Related]
52. Quercetin and rutin as potential agents antifungal against Cryptococcus spp.
Oliveira VM; Carraro E; Auler ME; Khalil NM
Braz J Biol; 2016; 76(4):1029-1034. PubMed ID: 27166572
[TBL] [Abstract][Full Text] [Related]
53. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
54. Amphotericin B. Old drug, new therapy.?2110.
Medoff G; Kobayashi GS
JAMA; 1975 May; 232(6):619-20. PubMed ID: 1091753
[No Abstract] [Full Text] [Related]
55. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis.
Clemons KV; Stevens DA
J Antimicrob Chemother; 1993 Sep; 32(3):465-72. PubMed ID: 8262869
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans.
Hossain MA; Maesaki S; Kakeya H; Noda T; Yanagihara K; Sasaki E; Hirakata Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jul; 42(7):1722-5. PubMed ID: 9661011
[TBL] [Abstract][Full Text] [Related]
57. Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report.
Vechi HT; Theodoro RC; de Oliveira AL; Gomes RMODS; Soares RDA; Freire MG; Bay MB
BMC Infect Dis; 2019 Mar; 19(1):220. PubMed ID: 30832607
[TBL] [Abstract][Full Text] [Related]
58. [Experimental animal studies with antimycotic substances. Part 2. Comparative studies on the effectiveness of peroral and subcutaneous application of amphotericin B on an experimental model of mice infected with Candida albicans, Cryptococcus neoformans, Mucor pusillus or Aspergillus fumigatus].
OSSWALD H; SEELIGER HP
Z Immun exp ther; 1960 Feb; 119():161-74. PubMed ID: 14429266
[No Abstract] [Full Text] [Related]
59. Therapy of deep-seated fungal infections with 5-fluorocytosine.
Firkin FC
Aust N Z J Med; 1974 Oct; 4(5):462-7. PubMed ID: 4616675
[No Abstract] [Full Text] [Related]
60. In vitro and in vivo activity of hamycin against Blastomyces dermatitidis.
Shadomy S; Robertson GM; Shadomy HJ; Utz JP; Gamble E
J Bacteriol; 1969 Feb; 97(2):481-7. PubMed ID: 5773006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
